EQS-News: Newron Pharmaceuticals S.p.A. / Key word: Conference/Study results
Newron presents exciting new data from study 014/015 at CINP World Congress of Neuropsychopharmacology and. | May 15, 2023
Ad hoc announcement pursuant to Art. 53 LR Newron Pharmaceuticals S.p.A. ("Newron") (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients
EQS-News: Newron Pharmaceuticals S.p.A. / Key word: Miscellaneous
Newron presents six-month interim data from the first 100 patients randomized in study 014/015 at the 31st European. | March 28, 2023
Study 014/015 is a Phase II trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia (TRS) Full data suggest a new strategy for the management of TRS patients
Presentation will include full data from the six-month interim timepoint from the cohort of the first 100 patients randomized in study 014/015, a Phase II trial evaluating evenamide as add-on therapy